https://www.selleckchem.com/pr....oducts/blebbistatin.
With a median follow-up of 10 years (range 5-27, mean 11.4) comprising 3,042 person-years, six SPMs developed of which only one (papillary thyroid carcinoma) was within the radiation field (crude rate of 0.38% of irradiated breasts/chestwalls), diagnosed 17 years after RT. This corresponds to an incidence of 0.32/1000 woman-years. The Kaplan-Meier estimate of 20-year freedom from a radiation-induced SPM is 99.5%. Calculated dose exposure to the out-of-field SPMs ranged from 0.1-1Gy. No patient developed an in-field skin cancer or s